Efficacy and safety of emerging immunotherapies in psoriasis.
about
Tildrakizumab for treating psoriasis.Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis.Meta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis.More Biologic Therapies Expected To Treat Advanced Plaque Psoriasis.Newer treatments of psoriasis regarding IL-23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors.Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis.MAPK Phosphatase-1 Deficiency Exacerbates the Severity of Imiquimod-Induced Psoriasiform Skin Disease.
P2860
Q39167757-47F0B146-FBB5-4F52-9E64-9707EE5A6C4DQ39275772-B3EA7244-A716-42F7-8007-D701D7AC8E17Q40090542-64B97D13-D0FB-4AA7-801F-C7DC09542547Q41967507-DA00AED8-AF6A-4BD7-9F54-6EA9A5CD5257Q47585528-0B1034D0-B55D-4967-875C-969906139CCFQ47786696-D876DD49-0B07-4344-9BB2-C9D6365FF0FAQ54117652-3A0EBB4D-3B67-476B-AE6B-44B77576E7E8
P2860
Efficacy and safety of emerging immunotherapies in psoriasis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Efficacy and safety of emerging immunotherapies in psoriasis.
@en
type
label
Efficacy and safety of emerging immunotherapies in psoriasis.
@en
prefLabel
Efficacy and safety of emerging immunotherapies in psoriasis.
@en
P2860
P356
P1433
P1476
Efficacy and safety of emerging immunotherapies in psoriasis
@en
P2093
Richard B Warren
Zenas Z N Yiu
P2860
P304
P356
10.2217/IMT.14.101
P577
2015-01-01T00:00:00Z